Publications by authors named "Courtney D DiNardo"

Claim this Profile
R
Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for -Mutated AML?
Jennifer Marvin-Peek, Courtney D DiNardo

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality and relapse dynamics in AML after three years of complete remission.
Samuel Urrutia, Wei-Ying Jen, Koji Sasaki, Peter H Wiernik, Tapan Kadia, Courtney D DiNardo

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia.
Wei-Ying Jen, Guilin Tang, Eitan Kugler, Jennifer Croden, Koji Sasaki, Courtney D DiNardo

Br J Haematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.
Carmelo Gurnari, Hideki Makishima, Arda Durmaz, Enrico Attardi, Ryunosuke Saiki, Courtney D DiNardo

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, Tapan M Kadia, Sanam Loghavi

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.
Christine E Birdwell, Warren Fiskus, Christopher P Mill, Tapan M Kadia, Naval Daver, Courtney D DiNardo

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.
Warren Fiskus, Lucia Masarova, Christopher P Mill, Christine E Birdwell, Kaberi Das, Courtney D DiNardo

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies.
Wei-Ying Jen, Sanam Loghavi, Alexandre Bazinet, Alex Bataller, Ian Bouligny, Courtney D DiNardo

Am J Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.
Antonino Glaviano, Ellen Weisberg, Hiu Y Lam, Donavan J J Tan, Andrew J Innes, Courtney D DiNardo

Nat Rev Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomolecular Mechanisms of Relapse and Post-Relapse Outcomes After Frontline FLT3 Inhibitor-Based Therapy in FLT3 -Mutated AML.
Sankalp Arora, Sanam Loghavi, Naval Daver, Farhad Ravandi, Courtney D DiNardo

Am J Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia.
Ahmed Aribi, Gabriel N Mannis, Yazan F Madanat, Brian A Jonas, Neil Dunavin, Courtney D DiNardo

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.
Reeja Raj, Samanta Catueno, Amber Gibson, David McCall, Miriam B Garcia, Courtney D DiNardo

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1.
Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, Xuemei Wang, Sanam Loghavi

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.
Guillaume Richard-Carpentier, Gopila Gupta, Charina Koraksic, Severine Cathelin, Lisa Wang, Courtney D DiNardo

Lancet Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy.
Sven Turkalj, Felix A Radtke, Bilyana Stoilova, Rabea Mecklenbrauck, Angus J Groom, Courtney D DiNardo

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, Vladimir Ivanov, Courtney D DiNardo

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.
Wei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek, Jessica K Altman, Musa Yilmaz, Courtney D DiNardo

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax.
Jennifer Croden, Wei-Ying Jen, Jennifer Marvin-Peek, Lianchun Xiao, Ian M Bouligny, Courtney D DiNardo

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.
Nicholas J Short, Sanam Loghavi, Musa Yilmaz, Omer Karrar, Kunhwa Kim, Courtney D Dinardo

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD123 expression and its correlation with mutation profile in acute myeloid leukaemia.
Roberta S Azevedo, Sa A Wang, David M Swanson, Naval G Daver, Naveen Pemmaraju, Courtney D DiNardo

Br J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRD intervention in AML: A new therapeutic horizon.
Andrew H Wei, Harry J Iland, Courtney D DiNardo, John Reynolds

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and Therapeutic Implications of Mutations in Acute Myeloid Leukemia.
Darren Lee, Yazan Abu-Shihab, Kate Plas, Deedra Nicolet, Krzysztof Mrozek, Courtney D DiNardo

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unveiling the Origins of Pathogenic Variants in Clinical Context: A Molecular Tumor Board Case Discussion.
Sanam Loghavi, Hiam Abdel-Salam, Danielle Hammond, Kelly Chien, Keyur P Patel, Courtney D DiNardo

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation.
Sankalp Arora, Wei-Ying Jen, Musa Yilmaz, Indraneel Deshmukh, Jayastu Senapati, Courtney D DiNardo

Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms.
Naseema Gangat, Courtney D Dinardo

Blood Cancer J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis